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Background: Radiotherapy, preferably combined with chemotherapy, is the treatment standard for locally
advanced, unresectable non-small cell lung cancer (NSCLC). The tumor response to different therapy protocols is
variable, with hypoxia known to be a major factor that negatively influences treatment effectiveness. Visualisation of
tumor hypoxia prior to the use of modern radiation therapy strategies, such as intensity modulated radiation
therapy (IMRT), might allow optimized dose applications to the target volume, leading to improvement of therapy
outcome. 18 F-fluoromisonidazole dynamic positron emission tomography and computed tomography (18 F-FMISO
dPET-CT) and functional magnetic resonance imaging (functional MRI) are attractive options for imaging tumor
hypoxia.
Methods/design: The HIL trial is a single centre study combining multimodal hypoxia imaging with 18 F-FMISO
dPET-CT and functional MRI, with intensity modulated radiation therapy (IMRT) in patients with inoperable stage III
NSCLC. 15 patients will be recruited in the study. All patients undergo initial FDG PET-CT and serial 18 F-FMISO
dPET-CT and functional MRI before treatment, at week 5 of radiotherapy and 6 weeks post treatment. Radiation
therapy is performed as inversely planned IMRT based on 4D-CT.
Discussion: Primary objectives of the trial are to characterize the correlation of 18 F-FMISO dPET-CT and functional
MRI for tumor hypoxia imaging in NSCLC and evaluate possible effects of radiation therapy on tumor re-
oxygenation. Further objectives include the generation of data regarding the prognostic value of 18 F-FMISO
dPET-CT and functional MRI for locoregional control, progression free survival and overall survival of NSCLC treated
with IMRT, which will form the basis for larger clinical trials focusing on possible interactions between tumor
oxygenation and radiotherapy outcome.
Trial registration: The ClinicalTrials.gov protocol ID is NCT01617980
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Lung cancer is the leading cause of cancer mortality.
The disease is worldwide diagnosed in about 1.35 mil-
lion patients yearly and is responsible for about 1.18 mil-
lion deaths yearly [1]. Non-small-cell lung cancer
(NSCLC) accounts for 75% of all cases. The treatment of
choice is surgery however a radical resection is possible
in only 20% of all cases. Radiation therapy alone or com-
bined with chemotherapy are therapeutic alternatives for
tumors that are surgically not resectable. Application of
60-66 Gy by external beam radiotherapy results in a
mean local tumor control of about 12 months [2],
whereas combined radio-chemotherapy, preferably plat-
inum-based, leads to a significant survival improvement
compared to irradiation alone [3].
Although there is evidence that dose escalation is
related with increased local control and improved overall
survival, a higher radiation dose is also related with
increased lung toxicity and severe side effects, such as
radiation induced pneumonitis and lung fibrosis [4]. To
reduce side effects, advanced technologies that allow a
more accurate dose delivery to the target volume minim-
izing healthy tissue toxicity have been developed. A
promising technology in this respect is the intensity
modulated radiation therapy (IMRT) [5].
Furthermore, use of fluorine-18 deoxyglucose dynamic
positron emission tomography and computed tomog-
raphy (FDG dPET-CT) improved disease staging,
whereas the development of four-dimensional computed
tomography (4D-CT) enabled a more precise target vol-
ume definition [6,7]. 4D-CT can improve radiotherapy
targeting, since it provides information about the motion
of the target but also about changes of the pulmonary
parenchyma as a result of breathing-associated changes
in air content [8,9]. In addition, advanced dynamic con-
trast enhanced magnetic resonance imaging (DCE-MRI)
techniques allow a better visualization of tumor hetero-
geneity, as well as an improved assessment of tumor
vascularization and more accurate differentiation be-
tween benign processes such as inflammation or atelec-
tasis and malignant tumor lesions [10,11].
However, despite the development of diagnostic and
therapeutic modalities, lung tumors still show a variable
resistance to available regimens of radio-chemotherapy.
One of the factors that increase therapy resistance is
hypoxia. Tumor hypoxia is associated with a malignant
phenotype, characterized by high invasiveness, increased
potential for progression and metastasis and poor prog-
nosis [12,13]. Subphysiologic levels of oxygen are present
in the majority of human tumors and lead to an up to
3-fold increase of resistance against antineoplastic strat-
egies [14].
The leading role of hypoxia in radiation resistance
reveals the necessity for the development and evaluationof hypoxia imaging assays. Such assays would allow a
better characterization of tumor heterogeneity and facili-
tate the improvement of targeted therapies, as well as
the development of novel strategies for prediction of
treatment outcome. An extensively investigated tracer
for visualization of tumor hypoxia by dynamic positron
emission tomography and computed tomography
(dPET-CT) is fluorine-18-labeled fluoromisonidazole
(18 F-FMISO; half time 110 min). Various preclinical and
clinical studies have revealed a correlation between oxy-
gen measurements and 18 F-FMISO uptake [15]. In
metastatic head and neck cancer, the retention of 18 F-
FMISO was found to be significantly greater in hypoxic
tumors, especially at pO2 values <5 mmHg [16]. A study
of 12 patients with head and neck carcinoma, who
received FMISO-PET scans before radiotherapy, revealed
that the tracer uptake was a prognostic indicator of
treatment response [17]. In regard to NSCLC, a study
performed in 14 patients demonstrated an association
between high tumor-to-muscle FMISO uptake ratios
and risk of relapse [18]. Furthermore, a trial of 8 patients
with NSCLC who were treated by combined radio-
chemotherapy and received serial 18 F-FMISO-PET scans
showed an association between FMISO uptake decrease
post treatment and favourable therapy outcome [19].
Further non-invasive methods for in vivo oxygenation
monitoring include modern magnetic resonance imaging
(MRI) and magnetic resonance spectroscopy (MRS)
applications. MRI approaches comprise perfusion func-
tional MRI for evaluation of tissue hemodynamics
through characterization of blood flow patterns, as well
as approaches based on the effects of local oxygen ten-
sion on the magnetic susceptibility effects of oxy- and
deoxyhemoglobin and on the effects of paramagnetic
oxygen on the relaxation times of tissue water [20].
Aim of the present trial is to investigate the correlation
of 18 F-FMISO dPET-CT and functional MRI for tumor
hypoxia imaging in patients with inoperable stage III
NSCLC, treated with 4D-CT based IMRT. Furthermore,
through serial 18 F-FMISO dPET-CT and functional MRI
investigations prior, during and post treatment, possible
effects of radiation therapy on tumor re-oxygenation




The HIL-trial has been designed by the study initiators at
the Clinical Cooperation Unit Radiation Oncology at the
German Cancer Research Center (DKFZ), the Clinical
Cooperation Unit Nuclear Medicine at DKFZ, the De-
partment of Radiology at DKFZ and the Department of
Radiation Oncology at the University of Heidelberg. The
trial is carried out at DKFZ in co-operation with the
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Heidelberg.
Coordination
The trial is coordinated by the Clinical Cooperation Unit
Radiation Oncology at DKFZ and the Department of Ra-
diation Oncology at the University of Heidelberg. DKFZ
is responsible for trial management and quality assur-
ance including reporting and database management.
Study design
The study is designed as a single centre trial with an ac-
crual of 15 patients with inoperable stage III NSCLC.
Patients fulfilling the inclusion criteria are treated with
intensity modulated radiation therapy (IMRT). All
patients undergo serial 18 F-FMISO dPET-CT and func-
tional MRI before treatment, at week 5 of radiotherapy
and 6 weeks post treatment. The trial workflow is
depicted in Figure 1.
Study objectives
Primary aim of the study is to characterize the correl-
ation of 18 F-FMISO dPET-CT and functional MRI for
tumor hypoxia imaging in patients with stage III NSCLC
treated with intensity modulated radiation therapyFigure 1 Trial workflow.(IMRT). This will be achieved through correlation be-
tween functional MRI parameters, such as diffusion
coefficients and 18 F-FMISO dPET-CT parameters, such
as standard uptake value (SUV) in matched regions of
interest. Further objectives are to evaluate changes in
18 F-FMISO dPET-CT and functional MRI parameters
during radiation treatment and characterize their prog-
nostic value for locoregional control, progression free
survival and overall survival.
Investigators
Patient treatment is performed by radiation oncologists
at the Clinical Cooperation Unit Radiation Oncology at
DKFZ. 4D-CT and functional MRI scans are performed
at the Department of Radiology at DKFZ. dPET-CT
studies are carried out at the Clinical Cooperation Unit
Nuclear Medicine at DKFZ.
Data handling, storage and archiving
All findings, including clinical and laboratory data, are
documented by the investigator or an authorized member
of the study team in the subject’s medical record. The in-
vestigator is responsible for ensuring that all sections are
completed correctly and that entries can be verified
against source data. All missing data or inconsistencies are
reported back to the investigators and clarified by the re-
sponsible investigator. If no further corrections are to be
made in the database it will be declared closed and used
for analysis. The data will be stored and archived accord-
ing to }13 of the German GCP-Regulation and }28c of the
German X-Ray Regulation (RöV) and }87 of the German
Radiation Protection Regulation (StrlSchV) for at least
30 years after the initial termination.
Ethics, informed consent and safety
The final protocol was approved by the ethics committee
of the University of Heidelberg, Heidelberg, Germany
(Nr: S-249/2009). The trial is sponsored by the Federal
Ministry of Education and Research (BMBF) of Germany
as part of the research fund “DOT-MOBI” (Nr.:
01IB08002B). This study complies with the Helsinki
Declaration and its recent German version, the Medical
Association code of conduct, the principles of Good
Clinical Practice (GCP) and the Federal Data Protection
Act. The trial is carried out in keeping with local legal
and regulatory requirements. The medical secrecy and
the Federal Data Protection Act are followed. The Clini-
calTrials.gov protocol ID is NCT01617980.
Patient selection
Inclusion criteria for the trial are:
 Documented inoperable, histologically confirmed
NSCLC stage III.
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at least 50% of the respective individual norm value).
 Karnofsky Performance Score of 70% or higher.
 Patients > 18 years of age.
 Adequate haematological function (wbc > 3000 × 103
/ml, thc >100 × 106 /ml, Hb > 10 g/dl)
 Adequate hepatic and renal function
 Written informed consent
Exclusion criteria for the trial are:
 Patient refusal
 Severe concurrent systemic disease
 Other malignancies




 Severe renal or hepatic insufficiency
 Pregnancy or lactationStudy plan
15 patients are included in the study according to the
criteria above. Eligible patients are informed about par-
ticipation in the trial with possible benefits and risks,
and written informed consent is obtained. Staging is
completed through performance of thoracic CT scan, ab-
dominal ultrasound and 18 F-FDG dPET-CT scan.IMRT treatment planning
After immobilization in a vacuum mattress a contrast-
enhanced thoracic CT scan including 4D respiratory
triggering is carried out. CT data are synchronized with
the recorded respiratory signal and 4D reconstructions
are performed to evaluate the motion of the thoracic
organs and the tumor during the breathing cycle. Based
on the 4D-CT data set, radiation treatment planning is
performed as inverse planning. 18 F-FMISO dPET-CT
and functional MRI data are not included in target vol-
ume definition or dose prescription.Radiation therapy
Radiation therapy is performed as intensity modulated
radiation therapy (IMRT). A dose of 50-54 Gy is applied
to the primary tumor and mediastinal lymph nodes in
daily fractions of 5 × 2 Gy. Subsequently, the primary
tumor and involved lymph nodes are boosted to a total
dose of 60-72 Gy in daily fractions of 5 × 2 Gy. Tolerance
doses of thoracic organs at risk are not exceeded.
Treatment is carried out on an out-patient basis un-
less the condition of the patient requires hospital
administration.18 F-FMISO positron emission tomography
18 F-FMISO is provided by Iason (Graz, Austria).
18 F-FMISO dPET-CT investigations are performed prior
to radiotherapy, at week 5 of radiation therapy and at
6 weeks post treatment. dPET-CT examinations are per-
formed after the i.v. injection of 18 F-FMISO using an
Biograph mCT S128 (Siemens Medical Solutions Co.,
Erlangen, Germany). The dynamic studies are acquired
with a 28-frame protocol for one hour. Quantification is
performed following the iterative reconstruction of the
dPET-CT data using a dedicated software package. Gen-
erally, volumes-of-interest (VOIs) are placed over the
tumor and reference regions, followed by a compart-
ment and non-compartment analysis. A two-tissue com-
partment model is the model of choice and five
parameters are obtained. The quantification includes the
calculation of the fractional blood volume, also named
as vessel density (VD), the parameters k1 and k2, which
reflect the influx and efflux of FMISO into and out of
the cells, and k3 and k4, which are related to the trap-
ping and re-oxygenation of FMISO. For the input func-
tion the mean value of the VOI data obtained from a
large arterial vessel like the descending aorta is used. Be-
sides the VOI based analysis, parametric images are cal-
culated to assess dedicated parameters of the FMISO
kinetics.
Furthermore, a non-compartment model based on the
fractal dimension is used. The fractal dimension (FD) is
a parameter for the heterogeneity and is calculated for
the time activity data of each individual VOI. The values
of the fractal dimension vary from 0 to 2 showing the
deterministic or chaotic distribution of the tracer activ-
ity. We use a subdivision of 7 × 7 and a maximal SUV of
20 for the calculation of FD. Details of the quantification
of the dPET data have been published elsewhere [21].
Functional MRI
Functional MRI investigations are performed prior to ra-
diation therapy, at week 5 of radiation therapy and at
6 weeks post treatment. All examinations are performed
using a clinical 1.5-T MRI scanner (Magnetom Avanto,
Siemens Medical Solutions, Erlangen, Germany).
The standard protocol comprises a coronal and a
transversal breath-hold TrueFISP, T2w single-shot half-
Fourier TSE (HASTE) and T1w 3D-GRE (VIBE) se-
quence. Afterwards, a navigator triggered transversal
T2w-FatSat sequence (T2-FS BLADE) is carried out.
Diffusion weighted imaging (DWI) is performed using
an axial single shot echoplanar (EPI) sequence with and
without flow-compensation. A total of ten b-values
(0, 10, 25, 50, 100, 200, 300, 400, 500 and 800 s/mm2) is
acquired, enabling extraction of diffusion and perfusion
parameters. DWI parameters are evaluated based on the
Intravoxel Incoherent motion (IVIM) model [22],
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constant D, using in house developed open-source soft-
ware MITK Diffusion, Version 2011 (downloadable at
www.mitk.org). The parameter estimation is based on
the assumption that the diffusion measurement is influ-
enced by mainly two effects, a perfusion related effect
introduced by the molecules moving in the capillary net-
work (pseudodiffusion coefficient, D*) and extravascular
effects of passive diffusion (D). Since a simultaneous
nonlinear fit for all parameters D, D*, and the weighting
coefficient f can be instable, measurement at b-values
greater than 200 s/mm2 are used in a first step to esti-
mate f and D as described [23]. D* is then calculated in
a second step by using exhaustive search.
Lung cancer perfusion is assessed using a spoiled 3D
gradient echo sequence after bolus injection of
0.07 mmol/kg body weight of Gd-DTPA. Ten acquisi-
tions in one expiratory breath hold (10 × 2.25 s = 22 s)
are followed by 50 navigator-triggered acquisitions under
free breathing (total TA 4½min). After a co-registration
of the 3D data sets, a ROI-based visualization of the
signal-time curves is performed as described [24].
Furthermore, a time-resolved echoshared gradient
echo sequence (TWIST) is performed for assessment of
three-dimensional tumor motion (240 × 0.5 s =TA
2 min). A dynamic 2D-TrueFISP sequence acquired in
coronal orientation crossing the centre of the tumor
provides additional information about lung and tumor
motion during the breathing cycle.
Contrast-enhanced sequences breath hold 3D-GRE se-
quence (VIBE) completes this protocol. The in-room
time for the complete protocol is approximately 30 min.
Clinical follow up
The first follow-up is planned 6 weeks post treatment
and includes study-related 18 F-FMISO dPET-CT and
functional MRI examinations. Further regular follow-up
visits are scheduled every 3 months for the first 2 years,
every 6 months for the following 3 years and thereafter
yearly. Individual trial participation is completed three
years after patient enrolment or death of the patient.
The therapeutic efficacy will be evaluated through
thoracic CT-scan at follow up visits.
Evaluation of local response
Local response evaluation is performed according to the
RECIST Criteria (Response Evaluation Criteria in Solid
Tumours) [25].
Statistical analysis
The study is a prospective and non-randomized trial
with inclusion of 15 patients. Repeated examinations
with 18 F-FMISO dPET-CT and functional MRI lead to
longitudinal data for every patient. The data consists ofmaps obtained from both measurement devices. Data
are quantitative measurements but may be dichotomized
or categorized into more than two classes. For all para-
meters, differences between the site of local relapse and
a selected control region are derived and compared by
paired tests at 5% level.
All analyses are exploratory. A sample size calculation
cannot be performed because neither standard deviation
of the differences has been estimated before, nor the
relevant difference is known. Therefore, the study will be
used to generate hypotheses for future research.
In the frame of the radiation therapy planning study,
virtual radiation therapy strategies will be compared to
the radiation therapy administered to the patient.
Discussion
Radiation therapy in combination with platinum-based
chemotherapy is the treatment of choice for inoperable
non-small-cell lung cancer. The development of modern
radiation delivery techniques, such as intensity-
modulated radiotherapy (IMRT) optimized treatment
planning, enabled better sparring of surrounding healthy
tissues and decreased treatment-related toxicity [26,27].
Compared with other cancer entities, in case of lung
cancer tumor motion during the breathing cycle and
variation of the target size due to changes in air content
of the pulmonary parenchyma enhance the complexity
of issues involved in radiation therapy planning, impede
the definition of target volume and limit IMRT. In re-
cent years, major progress has been made, mainly
through the development of four dimensional respiratory
triggering CT-scan planning modalities and MRI appli-
cations that allow a spatial resolution in the assessment
of tumor, healthy lung parenchyma, chest wall and dia-
phragm [28].
The outcome of radiation therapy is however often
limited by features of the tumor microenvironment. The
therapeutic effect of radiation therapy is known to be
negatively influenced by low tumor oxygen levels. There-
fore, better understanding of the correlation between ra-
diation resistance enhancing parameter, such as tumor
hypoxia, and outcome of radiation therapy applications
is of high priority for optimization of radiation therapy
strategies and improvement of treatment efficacy.
In this respect, visualization of tumor heterogeneity in
regard to hemodynamics and oxygen concentration is
necessary. Imaging applications for hypoxia assessment
include FMISO PET-CT and functional magnetic reson-
ance imaging. The use of FMISO in hypoxia specific
PET approaches is based on its selective reduction in
tumor regions with decreased oxygen concentration, and
the binding of its metabolites to macromolecules [15].
However, PET imaging is limited mainly through a
reduced spatial resolution. MRI provides high spatial
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tumor vasculature and perfusion, including important
anatomical details. Therefore, dPET-CT based investiga-
tion of variations in FMISO uptake and analysis of func-
tional MRI parameter can provide complementary data
about tumor vascularisation, microenvironment, func-
tional and anatomical structures.
Multimodal imaging studies in animal models were
combined with tissue section analysis to relate the
in vivo non-invasive data to the tumor microenviron-
ment. These studies demonstrated a positive correlation
between perfusion related, MRI-derived parameter with
early FMISO PET intensity and a negative correlation
with late FMISO slope, providing evidence for the hy-
pothesis that tumor regions with reduced perfusion are
hypoxic [29]. However, the same study also revealed
issues which should be considered in multimodal
approaches, such as volume averaging effects in PET as
a result of its lower spatial resolution and perfusion
effects of FMISO accumulation in the tumor [29]. Based
on these data, a clinical trial investigated tumor perfu-
sion using MRI and hypoxia measured by FMISO-PET
in 13 patients with nodal metastases of head and neck
cancer [30]. The results of this study also revealed a
negative correlation between FMISO uptake and the
perfusion value, supporting the hypothesis that hypoxic
tumors are poorly perfused [30].
Major pathophysiological mechanisms for the onset of
tumor hypoxia do not only include structural and func-
tional abnormalities of the tumor vasculature, which can
be assessed by perfusion protocols, but also adverse mo-
lecular diffusion. The diffusion geometry of tumors can
be assessed and visualized by diffusion-weighted MRI
(DWI). DWI has been successfully applied in various
clinical trials for determination and monitoring of treat-
ment response, indicating that lesions with locoregional
recurrence during follow-up correlated with significantly
lower diffusion [31].
Based on the empiricism of previous trials and on the
fact that, although single methods for non-invasive hyp-
oxia imaging are well established, still their complemen-
tary potential is not utilized, we designed the HIL trial.
Aim of this trial is the evaluation of multimodal tumor
hypoxia imaging using 18 F-FMISO positron emission
tomography and functional MRI in 15 patients with in-
operable stage III NSCLC, receiving 4D-planned inten-
sity modulated radiation therapy. We chose for our trial
NSCLC because of the major challenges that are asso-
ciated with this tumor entity, i.e. the tumor motion due
to changes in air content, which impedes the exact
image co-registration that is however necessary for
pixel-by-pixel comparisons. The HIL trial is an explora-
tory study. Data gained from this pilot investigation of
simultaneous, serial, multimodal approaches on hypoxiavisualization will form the basis for larger clinical studies
characterizing in detail possible interactions between
oxygen concentration and radiation outcome.
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